Nanjing Butterfly Pharma Packaging Completes Tens of Millions RMB Series A Financing to Accelerate Domestic Substitution and Global Expansion of High-End Pharmaceutical Packaging

VCBeat has learned that recently,Nanjing Batfulai Pharmaceutical Packaging Materials Co., Ltd. (hereinafter referred to as “Batfulai”) announced today the completion of its Series A financing, exclusively invested by Haofeng Capital, the CVC fund of Bloomage Biotech (688363.SH), with Ruohua Capital serving as the long-term exclusive financial advisor.This round of financing will be used for the commercial expansion of next-generation silicone oil-free pre-filled syringes, acceleration of international quality system certifications, and global market expansion.

Since its establishment in 2022, Batfulai has been dedicated to creating globally leading high-performance primary packaging solutions for injectables, utilizing cyclic olefin polymers (COC/COP) as the core material combined with a silicone oil-free lubrication system. Its flagship product, the silicone oil-free pre-filled syringe, leverages unique mold structures and fully automated production lines to achieve domestic technological breakthroughs, including ultra-low particulate levels, tungsten-free composition, and complete absence of silicone oil, thereby significantly enhancing drug safety and stability. The product has received dual filings with China’s Center for Drug Evaluation (CDE) and the U.S. Food and Drug Administration (FDA), and has been pioneered in mainland China for use in high-value-added products such as nanocrystal-based complex injectables and aesthetic medical devices.

“The successful completion of this funding round marks the capital market’s high recognition of Batfulai’s technical strength and commercialization capabilities,” said Gao Xingyu, founder of Batfulai. “We extend our gratitude to the Haofeng team and our colleagues at Bloomage Biotech for their trust and support. Leveraging this financing, we will further expand our product portfolio, accelerate technological innovation, and deepen international cooperation, driving China’s high-end pharmaceutical packaging materials from ‘import substitution’ to ‘setting standards.’”

Batfulai’s Spiral High-Viscosity Pre-filled Syringe Developed for High-Viscosity Formulations Such as Sodium Hyaluronate

Liu Kai, General Manager of Haofeng Capital, stated, “After several years of research and tracking in the pre-filled syringe industry, Batfulai is undoubtedly the standout among the innovative projects we have identified in this field. Batfulai has currently built a portfolio of proprietary products across multiple niche segments, including polymer-based silicone oil-free pre-filled syringes. Several of its products are establishing stable collaborations with leading downstream customers, validating the founding team’s profound insights and extensive experience in this domain, as well as their exceptional capabilities in R&D innovation and commercial implementation. Following this investment in Batfulai, Haofeng Capital will leverage its diversified industrial resources—particularly those of its key shareholder, Bloomage Biotech (688363.SH)—to provide long-term, multi-dimensional empowerment to Batfulai in areas such as product development and market expansion.”

Nanjing Batfulai Pharmaceutical Packaging Materials Co., Ltd. is dedicated to providing safe and efficient primary packaging solutions for injectables to global biopharmaceutical enterprises through material innovation and intelligent, advanced manufacturing. The company holds ISO 15378 quality management system certification, and its core team hails from the BioPharma and precision manufacturing sectors. It offers comprehensive technical support throughout the entire process, ranging from packaging design and pilot-scale production to customer simulation filling and commercial-scale production.

Haofeng (Hainan) Private Equity Fund Management Co., Ltd. (AMAC Private Fund Manager Registration No. P1074300, hereinafter referred to as “Haofeng Capital”) was established in 2022. It is an industrial capital platform jointly initiated by multiple industry players, focusing on early-stage and growth-stage investments. Leveraging industrial resources and using packaging innovation as a key driver, the company strategically focuses on four emerging areas—new materials, new processes, new technologies, and new services—within the consumer goods supply chain, particularly in cosmetics, food, and pharmaceuticals, with the aim of building a multi-party win-win industrial investment ecosystem.